Profile
General Information
The approval of these efficacy supplements provide for the use of Lamictal as conversion to monotherapy in adults with partial seizures who are receiving treatment with a single enzyme-inducing antiepileptic drug.
Approval Date: 1999-06-01
Date Created: 1999-07-15 12:00:00
Company Name: GlaxoSmithKline
